Key Takeaway:
- Major review finds new Alzheimer’s drugs slow decline but offer minimal real-life patient benefit.
- Treatments cost about £90,000, carry risks like brain swelling, and remain unfunded by the NHS.
- Findings trigger sharp scientific debate, with experts split over whether the drugs represent real progress.
A major independent Cochrane review Alzheimer’s drugs finds that expensive new Alzheimer’s drugs slow disease progression only marginally, raising doubts about patient benefit despite earlier breakthroughs, while triggering strong criticism from scientists who dispute the analysis.
Review Finds Limited Patient Benefit Despite Slower Decline
A sweeping Cochrane review Alzheimer’s drugs study of experimental Alzheimer’s treatments concludes that widely celebrated new drugs are unlikely to meaningfully improve patients’ lives, despite evidence that they slow cognitive decline.
The review, conducted by the Cochrane Collaboration, examined 17 clinical studies involving 20,342 volunteers receiving therapies designed to remove beta amyloid — a protein buildup linked to Alzheimer’s disease.
Researchers found the drugs reduced disease progression, but the effect was “well below” the threshold needed to produce noticeable improvements in daily functioning for patients.
The Cochrane review Alzheimer’s drugs’ conclusions challenge optimism surrounding antibody-based therapies such as donanemab and lecanemab, which previously marked the first time medications demonstrated an ability to slow brain degeneration associated with Alzheimer’s.
At present, Britain’s National Health Service does not fund the treatments. An 18-month course costs about £90,000 privately, placing them beyond the reach of most patients.
Researchers Warn Of Risks, Burden, and High Costs
The drugs work by using laboratory-engineered antibodies to identify and remove amyloid deposits between brain cells. While the approach represents a scientific milestone, researchers say practical benefits remain limited.
Prof. Edo Richard, a neurologist at Radboud University Medical Centre in the Netherlands and a co-author of the report, said physicians must provide realistic expectations.
“I would tell them, I think you will probably not benefit from these drugs, and they’re burdensome for you and your family,” Richard said. “It’s extremely important that we’re honest with our patients about what they can expect.”
The Cochrane review Alzheimer’s drugs study also highlighted safety concerns. Patients receiving treatment face risks, including brain swelling and bleeding, and must undergo infusions every two to four weeks.
Richard said future research should shift toward alternative approaches, including therapies targeting inflammation in the brain rather than focusing solely on amyloid removal.
Scientists Push Back, Calling Analysis Flawed
The Cochrane review Alzheimer’s drugs report has sparked a sharp backlash from other leading Alzheimer’s researchers, illustrating deep divisions within the scientific community over how progress should be measured.
Supporters of the analysis argue that early enthusiasm for the drugs may have overstated their real-world impact. Longtime critic Prof. Robert Howard of University College London said families affected by dementia may have been given unrealistic expectations.
“It is unfortunate and unfair that these drugs have been hyped in a way that is not supported by robust science and that will have raised false hopes,” Howard said.
Other scientists, however, contend the review undervalues incremental progress against a disease long resistant to treatment. They argue that even a modest slowing of decline could translate into additional months of independence for patients.
The debate around the Cochrane review Alzheimer’s drugs’ findings arrives at a pivotal moment for Alzheimer’s research, as regulators, health systems, and families weigh whether the clinical benefits justify high costs and medical risks.
For now, access remains limited, and uncertainty persists over whether the treatments represent a meaningful therapeutic advance or an expensive step toward future breakthroughs.
Visit more of our news! Healthcare 360 Magazine
